Yes, zwerp2000 was right about the company shutting down. We certainly were concerned about that since December 13, 2022, and the awful Midatech deal. That's why the stock dropped to 1¢. With Bioasis shareholders getting around 5% of Biodexa and with Biodexa stating that they were not going to be a drug delivery company, the deal was not much different than a failure of Bioasis in its affect on Bioasis shareholders.
But zwerp2000 and others have been saying more. They've been saying that xB3 is no good. That doesn't explain why Midatech, Ladenburg Thalmann and their clients wanted to buy Bioasis, why the original placee wanted ~95% of Biodexa, nor why the placee disappeared when Midatech shareholders voted the deal down. It looks to me that the placee wanted xB3 and disappeared when he couldn't have it.
zwerp2000's main beef has been that xB3 is no good and the evidence does not support that.
So, for the last couple of years, did Rathjen really work to save Bioasis? Or, with Ladenburg Thalmann, did she turn her attention to giving up on Bioasis and finding a new, private, home for xB3 and herself?
Were deals like the Ellipses deal shelved to keep the share price down to get the Midatech deal done?
Did Chiesi drop out because they have no interest in dealing with anybody associated with Ladenburg Thalmann? Or Lind?
zwerp2000 states the obvious about Bioasis failure but that is a simplistic take on it. I believe the failure of Bioasis is not the cause of anything. I believe the failure of Bioasis is due to long term incompetence at Bioasis, possibly combined with later greed and malice.
jd